PATH Inventprise

Inventprise is a clinical-stage biotechnology company specializing in the development of high-valent conjugate vaccines targeting infectious diseases that disproportionately affect global health. The company's lead program is IVT-PCV-25, a 25-valent pneumococcal conjugate vaccine developed in collaboration with PATH and supported by the Bill & Melinda Gates Foundation. Inventprise utilizes a proprietary linker technology designed to improve the stability and immunogenicity of complex vaccines while maintaining cost-effective manufacturing. Beyond its internal pipeline, the company operates as a contract manufacturing organization (CMO) providing process development and GMP manufacturing services for vaccines and biologics.